Bispecific Antibody Design
Description
This template was adapted from the original submission. Edits were made to enhance scientific accuracy, optimal usability and/or to meet industry-leading design standards for science communication.
(A) Illustrative representation of Blinatumomab, the only FDA approved bispecific antibody, designed to target CD3 (healthy T-cells) and CD19 (malignant hematologic tumors) through anti-CD3/CD19 single-chain variable fragments. (B) Mosunetuzumab, a bispecific antibody under clinical trial evaluation, is designed to target CD3 and CD20, where the CD20 targeting is achieved through the full-length domain of the antibody Fc domain.
Acknowledgements
References
Trabolsi, A et. al.. (2019) N/A. Journal of Immunology. https://doi.org/10.4049/jimmunol.1900496
Get started with this template for freeDon’t start from scratch.
Create professional scientific illustrations quickly and easily, even without any design expertise
- Get started with a huge library of editable icons and templates such as common biological pathways, anatomy, or genetics.
- Create figures that effectively communicate your research in half the time using our editable icons.
- Use our PDB tool to quickly generate and customize protein structures
.gif)
